OOIR: Observatory of International Research

Papers

(The TQCC of Current Atherosclerosis Reports is 12. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-08-01 to 2025-08-01.)

Article	Citations
Revascularization Options for Left Main Disease: What Clinicians Need to Know	88
Are Clinicians Aggressive Enough in Treating Diabetes-Related Hyperlipidemia in Youth?	84
Highlights of Cardiovascular Disease Prevention Studies Presented at the 2024 American Heart Association Scientific Sessions	81
Whether and Why Do We Need a Vaccine Against Atherosclerosis? Can We Expect It Anytime Soon?	78
Polysocial Risk Scores: Implications for Cardiovascular Disease Risk Assessment and Management	71
A Narrative Review of the Association Between Depression and Heart Disease Among Women: Prevalence, Mechanisms of Action, and Treatment	63
The Greatly Under-Represented Role of Smooth Muscle Cells in Atherosclerosis	59
The Expanding Scope of GLP-1 Receptor Agonists: Six Uses Beyond Diabetes	57
Glucagon-Like Peptide 1 Receptor Agonists: A Medication for Obesity Management	56
Heart Transplant, Kawasaki Disease, and Bone Marrow Transplant: Are There Consequences?	56
Ambient Air Pollution and Atherosclerosis: Recent Updates	54
Watermelon and l-Citrulline in Cardio-Metabolic Health: Review of the Evidence 2000–2020	52
The Effects of FABP4 on Cardiovascular Disease in the Aging Population	50
PCSK9 Inhibition and Risk of Diabetes: Should We Worry?	50
Polypharmacy and Cardiovascular Diseases: Consideration for Older Adults and Women	47
DOACs and Atherosclerotic Cardiovascular Disease Management: Can We Find the Right Balance Between Efficacy and Harm	43
Expanding Biology of PCSK9: Roles in Atherosclerosis and Beyond	43
Genetic Testing for Familial Hypercholesterolemia in Clinical Practice	42
From ‘Omics to Multi-omics Technologies: the Discovery of Novel Causal Mediators	41
Programmable Genome-Editing Technologies as Single-Course Therapeutics for Atherosclerotic Cardiovascular Disease	40
The Emerging Specialty of Cardio-Rheumatology	39
Inflammation in the Peri-ACS Period: Ready for Prime Time?	38
Nutrition Interventions for Youth with Dyslipidemia: Who, What, When, and Where?	36
Correction to: Beta‑blockers for Atherosclerosis Prevention: a Missed Opportunity?	36
The Role of Non-Statin Lipid Lowering Therapies to Reduce ASCVD Events in Primary Prevention	34

Recent Advances and Perspectives of Metabolomics-Based Investigations in Coronary Heart Disease	33
GLP-1 Receptor Agonists and Cardiovascular Disease: What Do Clinicians Need to Know?	33
The Intersection Between COVID-19, Cardiovascular Disease, and Diet: a Review	33
Percutaneous Coronary Interventions in Women	32
Myeloid Cells in Abdominal Aortic Aneurysm	31
Lipid Lowering Therapy Utilization and Lipid Goal Attainment in Women	31
RNA Silencing in the Management of Dyslipidemias	31
Lipoprotein(a): from Causality to Treatment	30
Implications of the Landmark ISCHEMIA Trial on the Initial Management of High-Risk Patients with Stable Ischemic Heart Disease	30
The Role of Sleep in Cardiovascular Disease	30
Low LDL-C: Is It all Good News?	29
Implementing Reporting Standards for Polygenic Risk Scores for Atherosclerotic Cardiovascular Disease	29
Role of RNA-binding Proteins in Regulating Cell Adhesion and Progression of the Atherosclerotic Plaque and Plaque Erosion	29
Novel Therapies for Lipoprotein(a): Update in Cardiovascular Risk Estimation and Treatment	29
Effects of Omega-3 Fatty Acids on Flow-mediated Dilatation and Carotid Intima Media Thickness: A Meta-analysis	26
Update on Plant-Based Diets and Cardiometabolic Risk	26
Coronary Microvascular Dysfunction: What Clinicians and Investigators Should Know	25
The Role of Bacterial Extracellular Membrane Nanovesicles in Atherosclerosis: Unraveling a Potential Trigger	25
Predicting Risk of Cardiovascular Disease EVENTs (PREVENT) Equations: What Clinicians Need to Know?	25
Childhood Hypertriglyceridemia: Is It Time for a New Approach?	24
In-Hospital Use of PCSK9 Inhibitors in the Post ACS Patient: What Does the Evidence Show?	24
Importance of Nutrition Security to CVD Prevention Efforts in the USA	23
Stress, Vascular Smooth Muscle Cell Phenotype and Atherosclerosis: Novel Insight into Smooth Muscle Cell Phenotypic Transition in Atherosclerosis	23
Transgender Cardiovascular Health: Practical Management for the Clinician	22
Correction to: High-Density Lipoproteins and Serum Amyloid A (SAA)	22
Recent Advances in Stent Technology: Do They Reduce Cardiovascular Events?	21
Is Family History for the Management of Cardiovascular Health in Youth Still Relevant in Clinical Practice?	21
Dairy Foods: Is Its Cardiovascular Risk Profile Changing?	21
Eliminating Health Disparities in Atrial Fibrillation, Heart Failure, and Dyslipidemia: A Path Toward Achieving Pharmacoequity	20
Evidence Gaps in Assessments of the Healthiness of Online Supermarkets Highlight the Need for New Monitoring Tools: a Systematic Review	20
Noninvasive Atherosclerotic Phenotyping: The Next Frontier into Understanding the Pathobiology of Coronary Artery Disease	20
Highlights of Cardiovascular Disease Prevention Studies Presented at the 2024 American College of Cardiology Conference	20
Membrane Cholesterol Interactions with Proteins in Hypercholesterolemia-Induced Endothelial Dysfunction	19
SR-B1’s Next Top Model: Structural Perspectives on the Functions of the HDL Receptor	19
Is There a Role for Imaging Youth at Risk of Atherosclerosis?	19
Do Triglyceride-Rich Lipoproteins Equal Low-Density Lipoproteins in Risk of ASCVD?	19
Major Concepts in Treatment with Bempedoic Acid and Inclisiran that Clinicians Need To Know	19
Brief Review: Racial and Ethnic Disparities in Cardiovascular Care with a Focus on Congenital Heart Disease and Precision Medicine	18
Gene Regulatory Networks in Coronary Artery Disease	18
Clinical Management of Dyslipidemia in Infants and Toddlers	18
Wall Shear Stress Alteration: a Local Risk Factor of Atherosclerosis	17
Cardiovascular Health and Disease in the Pakistani American Population	17
Pharmacotherapy for Coronary Artery Disease and Acute Coronary Syndrome in the Aging Population	17
Highlights of Cardiovascular Disease Prevention Studies Presented at the 2025 American College of Cardiology Conference	16
Biology, Bias, or Both? The Contribution of Sex and Gender to the Disparity in Cardiovascular Outcomes Between Women and Men	16
Natural Sirtuin1 Activators and Atherosclerosis: an Overview	16
Statin Use in Special Populations for the Prevention of Cardiovascular Disease in Adults	16
High Density Lipoprotein Particle Composition, Functionality, Deficiency, and Atherosclerotic Cardiovascular Disease Risk: A Review	16
Long-Term Cardiovascular Effects of COVID-19: Emerging Data Relevant to the Cardiovascular Clinician	16
Targeting the Gut Microbiome to Treat Cardiometabolic Disease	15

Bempedoic Acid: for Whom and When	15
Inclisiran, Reasons for a Novel Agent in a Crowded Therapeutic Field	15
What Causes Premature Coronary Artery Disease?	15
Combined Dyslipidemia in Children and Adolescents: a Proposed New Management Approach	14
Anti-Inflammatory Lipid Mediators from Polyunsaturated Fatty Acids: Insights into their Role in Atherosclerosis Microenvironments	14
Management of Hypercholesterolemia in Pregnant Women with Atherosclerotic Cardiovascular Disease	14
Utility of FFRCT in Patients with Chest Pain	14
A Review of Statin Intolerance: a Focus on Statin-Attributed Muscle Symptoms	14
Managing Dyslipidemia in Chronic Kidney Disease: Implications for Cardiovascular and Renal Risk	14
Managing of Dyslipidaemia Characterized by Accumulation of Triglyceride-Rich Lipoproteins	14
Circular RNA role in Atherosclerosis Development and Progression	13
The Role of Lysyl Oxidase in the Pathological Stage of Atherosclerosis: Structural Stabilizer or Disease Driver?	13
Controversies in the Use of Omega-3 Fatty Acids to Prevent Atherosclerosis	13
Fixed Combination for the Treatment of Dyslipidaemia	13
Non-obstructive Plaque and Treatment of INOCA: More to Be Learned	13
Extra-coronary Calcification and Cardiovascular Events: What Do We Know and Where Are We Heading?	13
Apheresis: What Should a Clinician Know?	12